Saxony’s biotech sector seeks more venture capital, faster approvals, and greater AI use to sustain growth. The state continues investing, expanding hubs like Bioz and Biocity,...
Eli Lilly warns that compounded tirzepatide mixed with vitamin B12 may form harmful impurities with unknown health effects. These untested combinations lack safety data and regulatory...
Novo Nordisk A/S (ISIN: DK0062498333) is a stable, growth-oriented biotech stock in 2026, driven by blockbuster drugs Ozempic and Wegovy. Dominating the diabetes and obesity markets,...
Eli Lilly has partnered with Dresden-based Seamless Therapeutics to develop a recombinase-based gene therapy for genetically caused hearing loss. Seamless will engineer precise recombinases, while Lilly...
Nvidia and Eli Lilly are launching a joint AI innovation lab in the San Francisco Bay Area to accelerate drug discovery and manufacturing. Backed by up...
Eli Lilly will invest $3 billion to build a new oral medication plant in Katwijk, Netherlands, creating 500 jobs. The facility will produce treatments for obesity,...
Eli Lilly will invest $3 billion to expand its Kenosha, Wisconsin, facility, acquired for $100 million in April. The site will manufacture injectable diabetes and obesity...
Eli Lilly posted a $970.3 million profit in Q3, boosted by 20.4% growth in sales despite a $1 billion loss in market value. Oversupply issues arose...
Eli Lilly is expanding its presence with the opening of a 346,000-square-foot facility in Boston, which will house 500 scientists and the first East Coast location...
Eli Lilly's first-half 2023 revenues surged 31% to $20 billion, driven by Mounjaro's $4.9 billion in sales, dominating the company’s earnings. Trulicity, in contrast, saw a...